BioSpace News Archive

Increasing production of complex nanorobots and development of nanoscale structures and devices are among the key factors driving the global market revenue growth.

Increasing prevalence of infectious diseases and life-threatening diseases such as Nipah and COVID-19 strains, high risk of emergence of novel diseases, and rising investments and funding by public and private organizations are expected to drive global market growth.

Growing incidence of canine atopic dermatitis and increasing expenditure on animal healthcare are key factors driving market growth.

Vector Remote Care, an industry pioneer in remote cardiac device monitoring with more than 250 years of collective cardiac expertise, today announced the launch of Vector Patient Care Platform, its new cardiac remote patient compliance and management software.

Brand Institute is proud to announce its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS®, under which the biosimilar approved by the Food and Drug Administration (FDA) on April 13, 2022 will be marketed.

SI-BONE, Inc. announced that the company will be participating in the upcoming 2022 Bank of America Healthcare Conference in Las Vegas.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the regulatory approval of Lymphoaim (“Lymphoseek” in the rest of the world; Tc99m tilmanocept) by the Central Drugs Standard Control Organisation, India.

Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced it will release its first quarter 2022 operating results on Wednesday, May 4, 2022 after market close, with a conference call to follow at 5:00 p.m. Eastern Time.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, announced today that it has entered into a definitive agreement to acquire Inform Diagnostics, a leading national independent pathology laboratory based in Irving, Texas, and a portfolio company of Avista Capital Partners.

-Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing single molecule protein sequencing, today announced that it will report financial results for the first quarter 2022 after market close on Monday, May 9, 2022.